Metabolic Dysfunction-Associated Steatotic Liver Disease Prevalence and Therapeutic Limits
Researchers at National Taiwan University addressed this unmet clinical need by developing a novel injectable self-healing hydrogel. The material is engineered to recapitulate the native hepatic microenvironment and restore liver function in MASLD. The findings were published in Advanced Healthcare Materials.
Professor Shan-hui Hsu develops chitosan-phenol hydrogel
The CPDP self-healing hydrogel was developed by Professor Shan-hui Hsu at National Taiwan University’s Institute of Polymer Science and Engineering.
In Vitro Validation Using Human iPSC-Derived Hepatocyte-Like Cells
The resulting composite hydrogel, termed 0.1% TA-CDS, incorporates tannic acid, the CPDP self-healing hydrogel, decellularized liver matrix, and hepatocyte spheroids. The material demonstrated significant therapeutic effects in an in vitro MASLD model.
Animal experiments demonstrate improved liver function
These results highlight the potential of the composite hydrogel as a promising therapeutic approach for MASLD.
Project Details and Investigator Information
Professor Yung-Te Hou can be reached via email at [email protected]. Additional details on the research are available through the Biomaterial and Tissue Engineering Lab at National Taiwan University.
Common Questions Regarding the National Taiwan University Hydrogel Study
What percentage of the global population is affected by MASLD?
Metabolic dysfunction-associated steatotic liver disease affects approximately 38% of the global population, with prevalence rising alongside metabolic syndrome.
How does the CPDP hydrogel achieve its self-healing capability?
The material forms through reversible Schiff-base crosslinking between the amine groups of chitosan-phenol and the benzaldehyde groups of difunctionalized polyethylene glycol, allowing bonds to break and reform after damage.
Which institutions collaborated on the iPSC-derived hepatocyte validation?
Researchers at National Taiwan University collaborated with Professor Kenji Osafune of Kyoto University (CiRA) to validate the therapeutic platform using human induced pluripotent stem cell-derived hepatocyte-like cell spheroids.
What specific duration of animal testing showed improved liver function?
Animal experiments demonstrated significant improvements in liver function, lipid metabolism, and serum biochemical markers after two weeks of treatment with the 0.1% TA-CDS composite hydrogel.
Related reading